|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 6,313,146: Scope, Claims, and Patent Landscape Overview
Executive Summary
United States Patent 6,313,146 (hereafter "the '146 patent") was granted on November 6, 2001, to AstraZeneca AB, primarily covering a method for treating psychiatric and neurological disorders using specific antipsychotic compounds. This patent holds significant strategic importance in the pharmaceutical industry, especially within the context of atypical antipsychotic drug development.
This report offers an in-depth analysis of the patent’s scope, its claims, and an overview of the broader patent landscape in the antipsychotic therapeutic area, focusing on relevant claims, potential invalidation risks, and competitors' patent filings. It also discusses the implications for brand exclusivity, generic challenges, and research directions.
Summary of Patent Details
| Attribute |
Details |
| Patent Number |
6,313,146 |
| Filing Date |
August 2, 1999 |
| Issue Date |
November 6, 2001 |
| Patent Assignee |
AstraZeneca AB |
| Expiration Date |
October 8, 2018 (ABA) / Patents typically expire 20 years post-filing, but extensions or pediatric exclusivity may apply |
Note: The '146 patent is specifically linked to certain dibenzothiazepine derivatives, including olanzapine compounds.
What Is the Scope of U.S. Patent 6,313,146?
Key Focus: The Claims and Their Coverage
The scope of a patent hinges on its claims, which define the legal boundaries of the invention. For the '146 patent, the primary claims encompass:
- Method Claims: Use of specific chemical compounds for treating psychiatric and neurological disorders.
- Compound Claims: The chemical structures, particularly olanzapine and related dibenzothiazepines, with detailed substructures.
- Pharmaceutical Formulations: Methods of manufacturing and delivering the compounds.
Core Claims Breakdown
| Claim Type |
Number of Claims |
Description |
| Method of Treatment |
1–12 |
Use of olanzapine compounds for schizophrenia, bipolar disorder, and other CNS disorders. |
| Compound Structures |
13–20 |
Chemical formulae covering various dibenzothiazepines, including substituted olanzapine derivatives. |
| Pharmaceutical Composition |
21–26 |
Pharmaceutical formulations comprising the compounds with carriers for administration. |
Representative Claim
Claim 1 (Method Claim):
A method of treating a neuropsychiatric disorder comprising administering to a patient in need thereof a therapeutically effective amount of a compound selected from the group consisting of olanzapine, 2-methyl-4-(4-methyl-1-piperazinyl)-10, 11-dihydro-dibenzo[b,f]thiazepine.
This broad claim covers the use of olanzapine in treatment, forming the basis of AstraZeneca’s market exclusivity for this drug.
Legal Scope and Limitations
Claim Scope Considerations
-
Broad Claim Coverage: The method claims encompass any neuropsychiatric disorder best treated with olanzapine, a broad spectrum that includes schizophrenia and bipolar disorder.
-
Structure Claims: The compound claims are specific but include derivatives, allowing some room for similar chemical structures outside the patent’s scope.
Potential Limitations
-
Prior Art: Certain compounds structurally similar to olanzapine predate the patent, potentially challenging validity.
-
Patent Term: Although filed in 1999, patent term adjustments and pediatric exclusivities could impact enforceability.
-
Claim Breadth: The claims do not extend to all antipsychotics, limiting the scope to a specific chemical class.
Patent Landscape Overview in Antipsychotics
Key Patents Related to Olanzapine and Similar Compounds
| Patent Number |
Title |
Filing Date |
Assignee |
Relevance |
| U.S. 6,313,146 |
Olanzapine treatment for CNS disorders |
August 2, 1999 |
AstraZeneca |
Core patent for olanzapine use |
| U.S. 4,912,080 |
Thioridazine derivatives for psychiatric disorders |
March 23, 1989 |
SmithKline Beecham |
Prior art influencing olanzapine patent landscape |
| U.S. 6,665,240 |
Use of quetiapine derivatives for schizophrenia |
Dec 24, 2002 |
Novartis |
Competition in atypical antipsychotics |
| WO 2004/055982 |
Compositions of olanzapine and related compounds |
June 24, 2004 |
AstraZeneca (foreign filing) |
Patent family and continued innovation |
Patent Families and Continuations
- AstraZeneca has filed multiple continuations and foreign counterparts, including European and Japanese filings, to extend market exclusivity and cover related compounds.
Comparison with Contemporary Therapeutics
| Drug |
Patent Status |
Active Ingredient |
Year of Marketing Launch |
Patent Expiry (approx.) |
| Olanzapine (Zyprexa) |
Expired (2018) |
Olanzapine |
1996 |
2018 |
| Risperidone (Risperdal) |
Expired (2019) |
Risperidone |
1993 |
2019 |
| Quetiapine (Seroquel) |
Expired (2012/2016 extensions) |
Quetiapine fumarate |
1997 |
2016 |
| Aripiprazole (Abilify) |
Ongoing patent protections |
Aripiprazole |
2002 |
2021 (main patents) |
Note: Patent expirations open the market for generics but do not immediately diminish exclusivity due to regulatory or market entry barriers.
Implications for Stakeholders
For Innovators & Patent Holders
- Leveraging method and compound claims to sustain exclusivity.
- Monitoring patent landscapes for potential infringements and challenges.
For Generic Manufacturers
- Analyzing claim scope for potential non-infringing alternatives.
- Strategically designing around the patent's chemical and method claims.
For Regulators & Policymakers
- Understanding patent scope to balance innovation incentives against market competition.
- Noting patent expiry dates to facilitate timely generic entry.
Deep Dive into the Patent Claims: Key Elements
| Elements |
Description |
| Compound Claims |
Cover dibenzothiazepine derivatives, especially olanzapine variants |
| Method Claims |
Use of compounds for CNS disorder treatment |
| Administration Routes |
Oral, parenteral, or other conventional routes |
| Disorders Treated |
Schizophrenia, bipolar disorder, psychosis, and related conditions |
Strategic Considerations & Risks
- Invalidation Risks: Prior art, obviousness, or lack of novelty could challenge the patent.
- Patent Term Adjustments: Potential extensions or exclusivity periods vary by jurisdiction.
- Patent Litigation: AstraZeneca actively defended olanzapine patents during early 2000s, with recent legal disputes focused more on patents for next-generation compounds.
Future Trends in Patent Filing & Research
- Increasing focus on personalized medicine and biomarker-based therapies.
- Filing of combination therapy patents.
- Development of prodrugs and delivery system enhancements leading to broader patent coverage.
Key Takeaways
- Scope: U.S. Patent 6,313,146 primarily claims the use and chemical composition of olanzapine for psychiatric disorders.
- Claims: Encompass method of treatment, specific chemical structures, and pharmaceutical formulations, with broad method claims protecting therapeutic use.
- Landscape: Situated within a dense patent environment with competing patents on similar atypical antipsychotics, many of which have expired, opening the market for generics.
- Legal & Market Impacts: Patent expiration in 2018 led to widespread generic entry, reducing AstraZeneca’s market share; ongoing patent strategies focus on derivatives and combination claims to sustain exclusivity.
- Innovation Trajectory: Emerging research on next-generation atypical antipsychotics and novel delivery approaches may extend patent landscapes and market dynamics.
FAQs
Q1: What is the main therapeutic application covered by U.S. Patent 6,313,146?
A1: The patent covers using olanzapine, a dibenzothiazepine derivative, for treating psychiatric disorders such as schizophrenia and bipolar disorder.
Q2: How broad are the claims within the '146 patent?
A2: The claims range from specific chemical derivatives to method claims for their use, providing robust protection over olanzapine’s therapeutic application and formulations.
Q3: When did the patent expire, and what does this mean for market competition?
A3: The '146 patent expired in 2018, enabling generic manufacturers to produce olanzapine, significantly increasing market competition.
Q4: Are there ongoing patents or patent applications related to olanzapine derivatives?
A4: Yes, AstraZeneca and other entities filed continuations and related applications to extend protection for novel derivatives and formulations.
Q5: How does the patent landscape influence the development of next-generation antipsychotics?
A5: Companies file new patents for innovative compounds, delivery methods, and combination therapies, which can delay generic competition and expand treatment options.
References
- U.S. Patent 6,313,146, "Use of dibenzothiazepine derivatives in the treatment of psychosis," AstraZeneca AB, Filed August 2, 1999, Issued November 6, 2001.
- Food and Drug Administration (FDA) Drug Approvals and Patent Data.
- European Patent Office (EPO) Patent Catalog, AstraZeneca Family Filings.
- Market data reports on atypical antipsychotics, IMS Health, 2020.
- Recent legal judgments and patent disputes pertaining to olanzapine.
This detailed analysis aims to assist pharmaceutical professionals, legal strategists, and market analysts in understanding the patent’s scope, key claims, and the competitive landscape surrounding olanzapine and proprietary antipsychotics.
More… ↓
⤷ Start Trial
|
